McPherson's Limited Overview
McPherson's Limited is a small-cap Australian brand owner in health and beauty. It traces its history to 1860 and is one of the oldest continuously operating companies on the ASX. After more than a decade of selling non-core businesses (printing, housewares, home appliances and, in 2024, Multix), it now focuses on five core brands. Manicare (beauty tools) and Swisspers (cotton) lead their categories in Australia, and Lady Jayne leads hair accessories. Dr. LeWinn's (anti-ageing skincare) and Fusion Health (herbal vitamins and supplements) are challenger brands in larger, faster-growing categories. Manufacturing is fully outsourced, mainly to Asia and Australia. Since FY25 the company has distributed through pharmacy wholesalers and a third-party logistics provider instead of delivering direct to stores. FY26 revenue was $118.3M and underlying EBITDA $4.3M. The company holds net cash, but faces a pending ASIC penalty and needs to show that its brands can grow under the new operating model.
What the company does
McPherson's markets and distributes beauty care, hair care, skin care, vitamins, supplements and personal-care items such as facial wipes, cotton pads and foot-comfort products. It operates in Australia, New Zealand and Asia (FY26 Directors' Report, Principal Activities). It does not manufacture. Production is outsourced to contract manufacturers mainly in Asia and Australia. It keeps a Hong Kong presence for sourcing and quality assurance, and a presence in the People's Republic of China for distribution and sales.
The company's own description (FY26 Annual Report, paraphrased): McPherson's describes itself as a leading supplier of health and beauty products. Most of its revenue comes from five core owned brands that lead their markets (Manicare, Dr. LeWinn's, Swisspers, Lady Jayne and Fusion Health), supported by portfolio brands including Maseur, Revitanail and Bondi fragrances. In the "Likely developments" section of the FY26 Directors' Report, it calls itself a "pure-play health and beauty company" focused on growing its brands.
Strategy framework (FY26 Investor Presentation, slide 9):
Purpose: "Making Confidence Simple."
Vision: to be Australia's leader in premium health and beauty products in every household, every day.
Where it plays: - Leadership positions in established categories: beauty tools, hair accessories, cotton and foot care.
- Challenger positions in larger, faster-growing categories: beauty transformation, facial skincare and vitamins, minerals and supplements (VMS).
Business and revenue model
| Dimension | Characterisation (FY26) |
|---|---|
| Product / service / subscription / licensing mix | About 100% branded physical products. There is no subscription or licensing revenue. A small, now-shrinking agency and distribution activity remains: an exclusive distribution agreement for Chemist Warehouse-owned brands outside the Chemist Warehouse network (from July 2022), and historically third-party agency brands that were mostly exited in FY24. |
| Owned vs portfolio | Core brands were 93.4% of FY26 revenue, up from 89.7% in FY25 (FY26 Presentation, slide 15). |
| Value chain position | Asset-light brand owner and marketer covering brand management, product development, sourcing and quality assurance, sales and A&P. Manufacturing, warehousing (third-party logistics provider from FY25) and much of pharmacy delivery (wholesalers) are outsourced. |
| Customer types | Major pharmacy chains, including Chemist Warehouse, the largest customer and a strategic-alliance partner since 2022; independent pharmacies, now served mainly through wholesalers (Symbion, API and at least one other large wholesaler); grocery (supermarket majors); specialty beauty; health food stores (important for Fusion Health); e-commerce marketplaces (Amazon); its own direct-to-consumer sites (Dr. LeWinn's and Fusion Health, launched in FY26); and international distributors, mainly China for Dr. LeWinn's. |
| End markets | Australian and New Zealand consumer health and beauty: beauty accessories, cotton, hair accessories, foot care, facial skincare and VMS. International sales were $2.6M in FY26, about 2.2% of revenue. |
| Key non-IFRS metric | CAAP (contribution after advertising and promotion) = gross margin less distribution costs and A&P. FY26 CAAP was $41.6M, a 35.2% margin. |
Independent characterisation
McPherson's is a sub-scale owner of consumer brands whose earnings depend heavily on a few Australian pharmacy and grocery buyers. Its three category leaders (Manicare, Swisspers and Lady Jayne) are, in effect, private-label-adjacent accessory brands. They have high shelf share but low pricing power, and they face competition from retailer house brands. The two growth brands, Dr. LeWinn's and Fusion Health, hold small shares (2.3% and 0.6% of their pharmacy categories) in large categories where multinationals dominate.
Divestments and the move to wholesalers have made the business simpler, but they also removed scale. Fixed costs fell faster than revenue only partly, and FY26 underlying EBITDA margin was 3.6%. The balance sheet is clean (net cash, undrawn facilities), and the shares trade below net tangible assets. The investment case now rests almost entirely on whether the company can restore revenue growth in FY27 on a lower fixed-cost base.
Strategy
Stated strategy themes (FY26 AR and Presentation, paraphrased)
-
Operate as a simplified, streamlined organisation focused on long-term brand growth. This is the main "Likely developments" theme in the FY26 Directors' Report.
-
"Concentrating investment behind fewer, bigger opportunities" (FY26 presentation, slide 9): five core brands, and the portfolio brands deliberately starved of A&P (portfolio revenue fell 45.9%).
-
How it competes:
-
Strong brands with creator-led marketing.
-
Disciplined innovation with "bigger, better launches".
-
Retail partnerships that grow customers' categories.
-
Its own direct-to-consumer channels and consumer relationships.
-
-
Where it reaches consumers:
-
ANZ retail (pharmacy, grocery, specialty beauty).
-
Digital and international (direct-to-consumer, online retailers, international partners).
-
Strategic initiatives, last 24 months
| Initiative | Dates | Targets / status |
|---|---|---|
| Route-to-market transformation (3PL plus pharmacy wholesalers) | Announced 24 Feb 2025; wholesalers signed Mar–Aug 2025; first full year FY26 | Target: $4.0–5.0M incremental annual EBIT from FY26, raised to the "upper end" in Jul 2025. Achieved: about $5.6M EBIT and about $2.8M EBITDA. Implementation material items: $9–11M expected in FY25. Pharmacy reach expanded to 4,521 independent pharmacies (IQVIA) from 3,562. |
| Five-core-brand focus; exit of private label and agencies | Announced 15 Nov 2023; completed FY24 | Core brands now 93.4% of revenue |
| Multix divestment | Jun 2024 | $19.0M proceeds |
| Direct-to-consumer e-commerce | FY26 | Dr. LeWinn's and Fusion Health sites launched; "encouraging" or "positive" growth |
| Amazon marketplace brand stores | FY26 | Several brand stores rolled out |
| Social and creator-led marketing model | FY26 build, FY27 deployment | Called a "foundation for FY27 growth" |
| Salesforce CRM and sales software | FY24–FY26 | Capitalised software is the main source of the rise in IT amortisation |
| ERP program | FY26 | $0.3M expensed as a material item |
| Branded point-of-sale display stands in major pharmacy | FY26 | Capitalised |
| Packaging refreshes | FY26–FY27 | Dr. LeWinn's completed; Manicare rolling out in FY27 |
| International distributor-led model | Decided FY26; implementation from FY27 | Aims to stop International's EBITDA losses (-$1.1M in FY26) |
| Debt refinancing | FY26 | $15M facility, undrawn |
| On-market buyback | Announced 25 Feb 2026 (up to $2M) | 4,995,130 shares bought for $0.8M by 30 Jun 2026 |
| Board renewal and committee restructure | FY26 | Three committees from 1 Feb 2026; NED minimum shareholding requirement |
| Sustainability: AASB S2 climate reporting readiness | Ongoing | Covered under governance (FY26 risk section) |
FY27 priorities and guidance (27 Aug 2026)
Priorities:
-
Joint business-development planning with customers.
-
Increasing wholesaler SKU availability of the bestseller list.
-
Creator-led consumer marketing.
-
More frequent launches backed by sustained A&P.
-
Greater investment in owned and marketplace e-commerce.
Guidance: Qualitative only. The company is "focused on delivering underlying EBITDA growth for the full year", while noting that weak 4Q26 sales continued into July 2026. No revenue guidance or medium-term financial targets have been published.
Products & Services
Pricing models are not disclosed for any brand. All products are sold wholesale to retailers at list price less trade terms and rebates; since FY25, independent pharmacy is served through wholesalers.
Core brands (all ANZ segment unless noted)
Manicare (beauty tools and accessories)
Description: Australia's leading beauty-accessories brand, covering tweezers, nail clippers and files, manicure and pedicure tools, makeup brushes and sponges, eyelash curlers and facial tools.
Market position: 36.3% value share of total beauty accessories (Circana, Australian grocery and pharmacy, MAT to 28 Jun 2026), category leader.
Target customer: Mass-market female consumers shopping in pharmacy and grocery.
FY26 launches: 12 products, including a Stainless Steel Gua Sha, Metal Face Roller and Silky Hair Bonnet. A packaging refresh began, rolling out in FY27.
Size: FY26 revenue $45.1M, the largest brand at about 38% of group revenue.
Channels: Pharmacy (chains and independents), grocery (grew in FY26 on price initiatives), and a major pharmacy customer (grew).
Watch: Increased competitive dynamics in parts of pharmacy. $2.3M brand impairment in FY26.
Swisspers (cotton and personal care)
Description: Cotton pads, cotton tips and buds, cotton balls, facial wipes and related cotton-care items.
Market position: 67.1% value share of cotton (Circana, 52 weeks to 28 Jun 2026), dominant category leader. MCP brand scan growth was 6.9% against category growth of 5.4%, gaining share.
FY26 launches: Cotton Variety Tips and a Baby Essentials Pack, extending into family care.
Size: FY26 revenue $21.8M (+1.0% reported, +4.1% like-for-like), the only core brand to grow.
Watch: Exposure to cotton commodity and freight costs. Part of a $1.3M combined impairment with Revitanail and Dr. LeWinn's.
Lady Jayne (hair accessories)
Description: Hairbrushes, combs, clips, pins, elastics, styling tools and bonnets.
Market position: 26.9% value share of total hair accessories (Circana, 52 weeks to 28 Jun 2026), category leader.
FY26 launches: Six styling products, including the Infinity Vent Brush, Chrome Shine Brush, Curl Definer Brush, Gem Top Brush, Large Acetate Detangling Comb and French Hair Pin. The brand was repositioned around effortless everyday style with the "Undone to Done" campaign.
Size: FY26 revenue $15.8M (-18.7% reported).
Watch: Ranging losses during the wholesaler transition, reduced promotions, and a delayed electrical range (hair tools).
Dr. LeWinn's (anti-ageing skincare; ANZ and International)
Description: Science-led, clinically inspired anti-ageing skincare with Australian origins. Formerly marketed under the "Dr. LeWinn's Private Formula" heritage; acquired with Revitanail around 2013–2014 (2014 AGM presentation). Includes neck, décolletage and facial treatments.
Named products: Plump + Lift Neck Cream; Smooth + Firm Neck & Décolletage Mask.
Market position: 2.3% of the $814M Australian pharmacy facial-skincare category (Circana, 52 weeks to 28 Jun 2026). Category grew 7.8% but the brand fell 17.8% in scan data.
FY26 developments: Completed a packaging refresh with benefit-led product architecture. Launched a direct-to-consumer e-commerce platform with encouraging growth.
Size: FY26 revenue $15.7M (-22.3%), hurt by out-of-stocks from the packaging refresh and supplier consolidation; resolved in 2H26.
International: China via distributor; weak demand and heavy competitor discounting.
History: Dr. LeWinn's China forecasts are central to the 2020 ASIC matter.
Fusion Health (herbal VMS)
Description: Herbal and nutritional supplements combining traditional Chinese medicine principles with modern herbal formulation. Established in 1999 and acquired with Oriental Botanicals from Blackmores in November 2020 for $27M.
Named products: Magnesium Sleep, Calm Mind and Calm Clear Focus (mental-wellbeing range launched FY26); Women's and Men's Multivitamins (relaunched at more competitive prices); historically an Immunity & Stress capsule.
Market position: 0.6% of the $2.0B Australian pharmacy VMS category. About 38% of brand sales go through the health-food channel, which scan data does not capture.
FY26 developments: Launched a direct-to-consumer e-commerce platform.
Size: FY26 revenue $12.1M (-22.1%).
Watch: Weak innovation performance and impairments of $1.9M in 1H26 and $2.1M for the full year.
Portfolio brands
| Brand | Category / description | Status (FY26) |
|---|---|---|
| Maseur | Foot comfort (massage sandals, insoles) | Listed among "iconic household brands" in FY26 releases. Impaired in FY24. |
| Glam | Beauty accessories / beauty transformation | Listed among iconic brands in the FY26 release. Detail not disclosed. |
| Revitanail | Nail treatments and strengtheners | Portfolio brand. Impaired in FY24 and FY26. |
| Bondi fragrances | Fragrance | Portfolio brand per the FY26 AR. Detail not disclosed. |
| Oriental Botanicals | Herbal VMS (practitioner origins; pharmacy since 2012) | Focus shifted to Fusion in FY24. Impaired in FY24. |
| Moosehead | Men's grooming | Listed in 2012–2017 materials. Current status not confirmed in FY26 sources. |
| A'kin / Al'chemy | Natural skincare and haircare (acquired Dec 2014) | Listed in FY23 materials. Absent from FY26 brand lists. Current status not publicly disclosed in the sources reviewed. |
| Chemist Warehouse brands (distributed under the exclusive distribution agreement) | Includes Wagner Vitamins, Wagner Body Science, Bondi Protein, Foster Grant, INC, Microgenics, distributed outside the CWG network | Agreement runs from 1 Jul 2022 for an initial five years. Revenue below expectations. The related inventory prepayment was fully impaired in FY24 ($3.7M impairment plus $1.2M amortisation). |
Exited or divested lines (last 5 years)
Multix: (bags, wraps, foils): sold June 2024.
Private label: exited FY24.
Agency brands: Sugarbaby (JV) and Eylure exited during FY24. Revenue from private label and non-strategic agency brands was $8.8M in FY23 and $4.7M in FY24.
Kotia: deer-milk skincare JV: status not disclosed in recent filings.
Historical agencies: P&G fine fragrances (Gucci, Dolce & Gabbana, Hugo Boss) from 2014, Trilogy (2014) and Karen Murrell. All are absent from recent filings.
Financial Narrative
Income statement
Sources: FY26 Remuneration Report five-year table (continuing NPAT, underlying NPAT, underlying EBITDA, EPS, dividends); FY23, FY24, FY25 and FY26 results releases; FY26 Presentation slides 15 and 27.
Table notes:
-
FY22 figures include Multix, which was continuing at the time.
-
FY25 total-group underlying EBITDA of $9.5M includes $2.2M from the discontinued Multix tail.
-
FY23 continuing statutory NPAT (-$1.3M) is from the FY26 five-year table. The FY24 release gives the FY23 group loss per share as 3.5 cents, the same figure the five-year table attributes to continuing operations; this is a disclosure inconsistency.
-
Group FY25 loss per share was 10.5 cents.
FY24 group basic loss per share was 11.1 cents: - Operating income (EBIT) is not presented on a statutory basis by the company. Statutory operating loss before finance costs was -$19.0M in FY25 and -$25.5M in FY26.
Revenue CAGR (continuing, FY23→FY26): -8.7% a year (calculated).
Revenue CAGR (total group basis, FY22→FY24): -3.9% a year (calculated).
Commentary. The revenue trend falls into three phases:
FY22–FY24 (portfolio pruning): Total revenue fell from $214.0M to $197.6M as private label and agencies were exited and Multix lost share to grocery private label.
FY24–FY25 (Multix removed, core brands steady): Continuing revenue fell 3.9%, of which $4.1M came from exiting non-strategic brands. Core brands grew 1.9%, helped by about $5M of transitional pipe-fill.
FY26 (transition shock): Revenue fell 14.9% (10.1% like-for-like). Of the $20.7M decline:
-
$7.1M came from accounting and route-to-market effects: wholesaler rebates now netted against revenue and the reversal of FY25 pipe-fill.
-
$7.4M came from underlying core-brand weakness.
-
$6.2M came from portfolio brands.
Gross margin rose 0.9 points to 58.8% because the mix shifted toward core brands, partly offset by rebate dilution. CAAP margin fell 2.8 points to 35.2% because 3PL distribution costs rose by $2.2M.
The key point is operating leverage. The new model removed $6.8M of employee costs and $1.4M of other costs, but CAAP fell by $11.2M, so underlying EBITDA fell $3.0M. Underlying NPAT has been roughly break-even for three years. The repeated statutory losses ($11.4M, $16.6M and $20.3M) come from impairments and restructuring, which total about $58M of pre-tax material items in continuing operations over FY23–FY26.
FY26 vs FY25 underlying cost structure
Structural benefits of the new model in FY26 (FY26 Presentation, slide 19):
-
Revenue/gross-margin line: -$3.2M.
-
Warehouse and logistics rebates: -$3.2M.
-
Distribution: +$1.7M from reduced delivery costs.
-
New 3PL services: -$3.4M.
-
-
Fixed costs (exit of warehouse staff and overheads): +$7.7M.
-
Net EBITDA benefit: about +$2.8M.
-
Depreciation and amortisation saved (Kingsgrove exit): +$2.8M.
-
Net EBIT benefit: about +$5.6M, slightly above the original $4–5M EBIT target.
Material items
Table notes: - FY24 impairments include $3.7M on the Chemist Warehouse distribution prepayment (plus $1.2M of amortisation) and $2.8M on other non-core brands.
-
The FY25 component split is only partly disclosed. Impairment was $10.2M per the income statement; the rest covered redundancy, onerous lease ($3.2M) and other items, offset by a $1.3M foreign currency translation reserve gain.
-
FY26 impairments were $15.0M of goodwill (ANZ) and $5.7M of brands (Manicare $2.3M, Fusion $2.1M, and $1.3M across Swisspers, Revitanail and Dr. LeWinn's).
-
FY26 total also includes the $2.3M ASIC costs, a $0.8M onerous lease, and $0.3M of ERP costs, less a $0.1M ATO interest benefit.
-
The $2.0M ASIC penalty provision recognised after balance date is included within FY26 provisions and other items.
Balance sheet
Sources: FY26 consolidated balance sheet; FY24 results release (net cash $14.1M; FY23 net debt $6.5M); FY26 statement of changes in equity (FY24 closing equity $89.6M); FY25 cash flow statement (FY24 closing cash $24.8M).
Table notes:
Net cash excludes lease liabilities: - Discrepancy: FY26 balance-sheet cash ($5.110M) less borrowings ($0.345M) is $4.8M, but the company reports net cash of $4.5M. The sources do not reconcile the $0.3M gap; the company figure is shown.
-
NTA per share: the 4E table header order suggests FY25 19c and FY26 20c, consistent with calculated tangible equity (about $26.8M FY25 and $27.3M FY26).
-
FY26 accumulated losses were $167.4M against contributed equity of $216.4M. This retained-loss balance is the stated reason no dividends can be paid.
Debt facility: Refinanced during FY26 to a $15M facility "right-sized" for the new model. It was undrawn throughout FY26 and the company states it complied with covenants (FY26 AR Note 1(a) and Note 18). Covenant terms and maturity are not disclosed in the sources reviewed.
Commentary. The balance sheet is simpler and contains less goodwill after FY26. Intangibles fell from $46.2M to $24.5M, so the risk of further write-downs is now lower in dollar terms. Inventory rose 32% to $26.2M to fix the Dr. LeWinn's out-of-stocks and buffer uneven wholesaler orders, which consumed most of the year's cash. The going-concern assessment explicitly considered the ASIC penalty, but the auditor did not raise a material uncertainty.
Cash flow
Sources: FY26 and FY25 cash flow statements; FY24 results release. FY23 operating cash flow is from the FY24 release. Underlying cash conversion was 51% in FY23 and 129% in FY22 (FY23 release).
FY26 operating cash flow includes a $2.0M ATO refund announced on 19 Feb 2026. Without it, operating cash flow would have been about -$1.3M. FY24 dividends were 2.0c per share paid on 22 Mar 2024; the cash amount is not in the sources reviewed.
Commentary.
-
Cash generation has weakened sharply: operating cash flow fell from $12.3M in FY24 (helped by inventory release) to $0.7M in FY26.
-
After lease payments, the business consumed about $3.5M of cash in FY26.
-
The 1H26 position ($12.6M net cash at 31 Dec 2025) turned into $4.5M by June 2026. This came from the inventory rebuild, payment in July 2025 of restructuring costs, the buyback, and weak 2H trading.
Risk: If FY27 earnings do not recover, the combination of the ASIC penalty (provision $2.0M; the actual penalty could be "materially higher or lower") and leftover Kingsgrove lease costs could push the company into net debt.
Ratios
Ratios are calculated from the financial statements: - ROIC uses a 30% tax rate and invested capital = equity + borrowings + leases − cash.
-
Negative net-debt-to-EBITDA means net cash.
-
Working-capital day counts are distorted: receivables include GST and are gross of rebates and claims, and payables include A&P, rebate and customer-claim accruals. Trend the figures; do not compare them with peers.
-
A cash conversion cycle cannot be computed reliably; the indicative figure is about 45–50 days, a blunt approximation.
Commentary.
-
Returns are negative on a statutory basis and close to zero on an underlying basis.
-
Liquidity is adequate (current ratio about 1.5×) and financial gearing is negligible.
-
Operational gearing is the problem: a fixed-cost base of about $37M (employee plus other costs) sits on about $42M of CAAP. Every 1% of revenue lost costs about $0.35M of EBITDA at the FY26 CAAP margin.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Products / brands |
|---|---|---|
Australia and New Zealand (ANZ) | All domestic sales into pharmacy (chains and, through wholesalers, independents), grocery, specialty beauty, health food, Australian and NZ e-commerce and direct-to-consumer. Goodwill is allocated to the ANZ cash-generating unit. | Manicare, Swisspers, Lady Jayne, Dr. LeWinn's, Fusion Health, Maseur, Glam, Revitanail, Bondi fragrances, and Chemist Warehouse brands under the exclusive distribution agreement |
International | Export and offshore sales, mainly Dr. LeWinn's in China. Historically included Singapore agency and distributor sales, exited in FY24. A move to a distributor-led model is to start in FY27. | Dr. LeWinn's (main), Manicare (small) |
Corporate (unallocated) | Group costs. Segment EBITDA excludes corporate costs. | — |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ANZ revenue (AUD Mn) | 146.6 | 139.1 | 135.9 | 115.8 |
International revenue (AUD Mn) | 9.3 | 5.6 | 3.0 | 2.6 |
Group revenue continuing (AUD Mn) | 155.2 | 144.6 | 139.0 | 118.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ANZ underlying EBITDA (AUD Mn) | 17.6 | 12.8 | 12.9 | 9.6 |
International underlying EBITDA (AUD Mn) | -1.3 | -0.6 | -1.6 | -1.1 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ANZ EBITDA margin (%) | 9.2 | 9.5 | 8.3 |
International EBITDA margin (%) | -10.7 | -53.3 | -42.3 |
ANZ revenue YoY growth (%) | -5.1 | -2.3 | -14.8 |
International revenue YoY growth (%) | -40.5 | -46.4 | -16.3 |
ANZ share of group revenue (%) | 96.1 | 97.8 | 97.9 |
International share of group revenue (%) | 3.9 | 2.2 | 2.2 |
Revenue by Segment (FY2025–FY2026)
| Brand (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Manicare | 47.9 | 45.1 |
Swisspers | 21.6 | 21.8 |
Lady Jayne | 19.4 | 15.8 |
Dr. LeWinn's | 20.2 | 15.7 |
Fusion Health | 15.6 | 12.1 |
Total core brands | 124.6 | 110.5 |
Revenue by Segment (%)
| Brand performance (%) | FY26 reported growth (%) | FY26 like-for-like growth excl. rebates and pipe-fill (%) |
|---|---|---|
Manicare | -5.7 | -0.1 |
Swisspers | 1.0 | 4.1 |
Lady Jayne | -18.7 | -14.4 |
Dr. LeWinn's | -22.3 | -15.5 |
Fusion Health | -22.1 | -16.9 |
Core brands total | -11.3 | -6.1 |
Portfolio brands total | -45.9 | -44.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Core brand revenue (AUD Mn) | 122.4 | 124.6 | 110.5 |
Core brand share of revenue (%) | 84.6 | 89.7 | 93.4 |
Revenue by Segment (1H2025–1H2026)
| Brand (AUD Mn) | 1H2025 | 1H2026 |
|---|---|---|
Manicare | 23.9 | 25.5 |
Swisspers | 10.5 | 11.8 |
Lady Jayne | 9.6 | 9.4 |
Dr. LeWinn's | 10.9 | 8.6 |
Fusion Health | 7.6 | 6.7 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue total group incl Multix (AUD Mn) | 214.0 | 210.3 | 197.6 | — | — |
Revenue continuing ops (AUD Mn) | — | 155.2 | 144.6 | 139.0 | 118.3 |
Gross profit continuing (AUD Mn) | — | — | — | 80.5 | 69.6 |
Gross margin continuing (%) | — | — | — | 57.9 | 58.8 |
A&P expense continuing (AUD Mn) | — | — | — | 22.3 | 20.5 |
CAAP continuing underlying (AUD Mn) | — | — | — | 52.8 | 41.6 |
Underlying EBITDA total group (AUD Mn) | 17.5 | 15.0 | 15.2 | 9.5 | 4.3 |
Underlying EBITDA continuing (AUD Mn) | 17.5 | 12.1 | 7.7 | 7.3 | 4.3 |
Underlying EBITDA margin continuing (%) | 8.2 | 7.8 | 5.3 | 5.2 | 3.6 |
Underlying EBIT continuing (AUD Mn) | — | — | — | 0.7 | 0.2 |
Material items pre-tax continuing (AUD Mn) | — | 3.7 | 12.7 | 19.7 | 25.6 |
Statutory pre-tax profit continuing (AUD Mn) | — | — | — | -19.7 | -25.7 |
Underlying NPAT continuing (AUD Mn) | 7.0 | 2.3 | -0.4 | -0.1 | -0.5 |
Statutory NPAT continuing (AUD Mn) | 0.3 | -1.3 | -11.4 | -16.6 | -20.3 |
Statutory NPAT total group (AUD Mn) | 0.3 | -5.1 | -16.0 | -15.0 | -20.3 |
Statutory net margin continuing (%) | 0.2 | -0.8 | -7.9 | -11.9 | -17.1 |
Basic EPS continuing (AUD cents) | 0.3 | -3.5 | -7.9 | -11.5 | -14.2 |
Underlying EPS continuing (AUD cents) | 5.3 | 1.6 | -0.3 | 0.0 | -0.3 |
Diluted EPS continuing (AUD cents) | — | — | — | -11.5 | -14.2 |
Dividends per share (AUD cents) | 5.0 | 3.0 | 2.0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBusiness Lines
| Line | FY2025 | FY2026 |
|---|---|---|
Revenue (AUD Mn) | 139.0 | 118.3 |
Gross margin (AUD Mn) | 80.5 | 69.6 |
Distribution costs (AUD Mn) | 5.3 | 7.5 |
A&P (AUD Mn) | 22.3 | 20.5 |
CAAP (AUD Mn) | 52.8 | 41.6 |
Employee costs (AUD Mn) | 31.7 | 24.9 |
Other expenses (AUD Mn) | 13.8 | 12.4 |
Underlying EBITDA (AUD Mn) | 7.3 | 4.3 |
Depreciation and amortisation (AUD Mn) | 6.5 | 4.1 |
Underlying EBIT (AUD Mn) | 0.7 | 0.2 |
Components
| Component | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Intangible impairments (AUD Mn) | 6.5 | 10.2 | 20.7 |
Restructuring and transformation (AUD Mn) | 1.7 | — | 1.5 |
ASIC legal and regulatory costs (AUD Mn) | — | — | 2.3 |
Total material items continuing (AUD Mn) | 12.7 | 19.7 | 25.6 |
Balance Sheet and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Total assets (AUD Mn) | — | — | 117.2 | 96.9 |
Cash and equivalents (AUD Mn) | — | 24.8 | 9.5 | 5.1 |
Inventories (AUD Mn) | — | — | 19.8 | 26.2 |
Trade and other receivables current (AUD Mn) | — | — | 29.5 | 30.5 |
Intangible assets incl goodwill (AUD Mn) | — | — | 46.2 | 24.5 |
Borrowings current (AUD Mn) | — | — | 0.7 | 0.3 |
Borrowings non-current (AUD Mn) | — | — | 0 | 0 |
Lease liabilities total (AUD Mn) | — | — | 6.6 | 5.8 |
Net cash company definition (AUD Mn) | -6.5 | 14.1 | 8.8 | 4.5 |
Total equity (AUD Mn) | — | 89.6 | 73.0 | 51.8 |
Working capital current assets less current liabilities (AUD Mn) | — | — | 22.9 | 21.3 |
Trade working capital receivables plus inventory less payables (AUD Mn) | — | — | 20.7 | 24.8 |
NTA per share (AUD cents) | — | — | 19 | 20 |
Cash Flow
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Operating cash flow (AUD Mn) | 6.5 | 12.3 | 2.2 | 0.7 |
Capex PP&E plus intangibles (AUD Mn) | — | 2.7 | 3.6 | 1.3 |
Free cash flow OCF less capex (AUD Mn) | — | 9.6 | -1.4 | -0.6 |
Lease principal repayments (AUD Mn) | — | — | 3.7 | 2.9 |
Free cash flow after leases (AUD Mn) | — | — | -5.1 | -3.5 |
Dividends paid (AUD Mn) | — | — | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0.8 |
Net borrowing repayment (AUD Mn) | — | — | 10.2 | 0.1 |
Divestment proceeds (AUD Mn) | 0 | 19.0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE statutory on average equity (%) | -18.5 | -32.5 |
ROA statutory on average assets (%) | — | -18.9 |
ROIC underlying after-tax EBIT on invested capital approx (%) | 0.7 | 0.3 |
Current ratio (x) | 1.61 | 1.51 |
Debt to equity borrowings only (%) | 0.9 | 0.7 |
Debt to equity incl leases (%) | 10.0 | 11.9 |
Net debt to underlying EBITDA (x) | -1.2 | -1.0 |
Interest coverage underlying EBIT over borrowing costs (x) | 0.7 | 0.4 |
Asset turnover (x) | — | 1.10 |
Days sales outstanding approx (days) | 77 | 94 |
Days inventory on materials cost approx (days) | 123 | 196 |
Days payables on materials cost approx (days) | 178 | 240 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia and New Zealand (AUD Mn) | 146.6 | 139.1 | 135.9 | 115.8 |
International mainly China (AUD Mn) | 9.3 | 5.6 | 3.0 | 2.6 |
Growth (%)
| Growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ANZ YoY growth (%) | -5.1 | -2.3 | -14.8 |
International YoY growth (%) | -40.5 | -46.4 | -16.3 |
Share Price and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at fiscal year end (AUD) | 0.66 | 0.40 | 0.41 | 0.25 | 0.14 |
Dividends per share (AUD cents) | 5.0 | 3.0 | 2.0 | 0 | 0 |
Performance Details
| Performance (price only, fiscal-year-end basis) | Value |
|---|---|
1-year (Jun 2025 → Jun 2026) | -44% |
3-year (Jun 2023 → Jun 2026) | -65% |
4-year (Jun 2022 → Jun 2026) | -79% |
5-year | Not available (FY21 year-end price not in sources reviewed) |
Since FY26 year end (Jun 2026 → about 1 Sep 2026) | About -11% |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | About A$17.4M | Derived |
Enterprise value excluding leases | About A$12.9M | Market cap less $4.5M net cash |
EV including leases | About A$18.7M | Plus $5.8M lease liabilities |
EV / underlying EBITDA FY26 | About 3.0× (excluding leases) | $4.3M EBITDA, which is pre-AASB 16 adjusted only in part |
EV / Sales FY26 | About 0.11× | $118.3M revenue |
Price / Book | About 0.34× | $51.8M equity |
Price / NTA | About 0.63× | 20c NTA per share |
Peer multiples | Not compiled | No comparable ASX peer set |
Analyst Conclusions
Management guidance
FY27: Qualitative only. The company is "focused on delivering underlying EBITDA growth" from the FY26 base of $4.3M. It acknowledges that weak sales continued into July 2026. No revenue guidance.
Long-term incentive hurdles (not guidance): FY28 underlying EPS of 2.27–3.67c, implying underlying NPAT of about $3.2–5.1M.
Consensus expectations
Not available (no broker consensus identified).
Bull case
-
Costs fixed; recovery depends on revenue. The new model has permanently removed about $7.7M of fixed costs and $2.8M of depreciation. If like-for-like core-brand revenue simply returns to FY25 levels (about $124M, versus $110.5M in FY26) at a CAAP margin of about 35%, underlying EBITDA could plausibly double from $4.3M. Much of the FY26 hit came from one-off transition effects ($7.1M of rebate and pipe-fill impacts) and from out-of-stocks that are now fixed.
-
Leadership brands are intact. Manicare, Swisspers and Lady Jayne all kept their category-leading shares, and Swisspers gained share. Distribution has widened by about 950 pharmacies. When wholesaler SKU optimisation fixes ranging, this wider reach could turn into volume, as already seen with the largest wholesaler (sales and volumes up in FY26).
-
Asset backing and optionality. EV is about $13M, against $4.3M of EBITDA, net cash and NTA of 20c against a share price of about 12.5c. The brands are market leaders. That creates downside support and possible corporate interest, for example from Chemist Warehouse, which is already a strategic shareholder and alliance partner.
Bear case
-
Structural share loss, not just transition. Brands declined in four of five growing categories. Fusion and Dr. LeWinn's are falling 15–17% like-for-like, and portfolio brands fell 44%. Management has missed its own guidance three times in six months (February, April and July 2026).
-
Overhangs cluster in 2027. The ASIC penalty hearing (April 2027) and the end of the Chemist Warehouse alliance's initial term (June 2027) both fall in the same window. Either could hit cash, ranging or sentiment, at a time when net cash is only $4.5M and free cash flow after leases is negative (about -$3.5M in FY26).
-
Sub-scale economics. At about $118M of revenue, a fixed base of about $37M (employee plus other costs) and $20M of A&P leave little room for error. More impairments are possible on the remaining $24.5M of intangibles if FY27 forecasts are missed, and retained losses rule out dividends for the foreseeable future.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Oct–Nov 2026 | 2026 AGM: trading update for 1Q–early 2Q FY27; remuneration report vote (strike risk after nil STI and a statutory loss); any chair succession signals |
| Ongoing | Wholesaler SKU ranging gains; Circana share trends for Manicare, Lady Jayne and Dr. LeWinn's |
| Feb 2027 | 1H27 results: like-for-like core-brand growth, CAAP margin recovery, net cash, buyback status |
| 6 Apr 2027 | ASIC penalty hearing (or an earlier appeal decision) |
| By 30 Jun 2027 | Chemist Warehouse strategic alliance renewal or renegotiation; expiry of the Kingsgrove lease (22 Jun 2027), which removes a residual cost |
| FY27 | Execution of the international distributor model; direct-to-consumer and Amazon scale; launch frequency and success, especially Fusion's mental-wellbeing range and Lady Jayne's electrical range |
| Any time | Corporate activity (none disclosed); substantial-holder changes |
Analyst verdict
McPherson's has completed the restructuring that its last three CEOs worked toward. It has exited printing, housewares, appliances, Multix, private label, agencies and its own warehouse, leaving a pure-play portfolio of health and beauty brands with an asset-light cost base and no debt. The problem is that this restructuring has not produced profitable growth.
FY26 was intended to be the first year in which the new route to market paid off. Instead, revenue fell 14.9% and underlying EBITDA fell 41%, and a further $20.7M of intangibles was written off. The structural savings of $5.6M at EBIT level were delivered as promised, but trading losses more than absorbed them. The execution misses were Dr. LeWinn's out-of-stocks, delayed launches, weak innovation at Fusion and ranging losses in independent pharmacy. Management's guidance was revised three times in six months.
At about A$0.125 per share the market is pricing the company as being in steady decline. The enterprise value of about $13M is about 3× FY26 EBITDA, and the shares trade at roughly 0.6× NTA. That price does not credit category-leading positions of 36–67% in beauty tools and cotton, or a fixed-cost base that has finally been reset. If like-for-like core-brand revenue can be stabilised in 1H27, the operating leverage is meaningful. If it cannot, the 2027 cluster of risks (ASIC penalty, Chemist Warehouse renewal, a thin cash buffer and possibly further impairments) leaves little margin for error.
Our assessment is speculative and execution-dependent, with a negative near-term skew. The thesis can be tested quickly: 1H27 results in February 2027 must show positive like-for-like growth in core brands, a recovery in CAAP margin and stable net cash. Absent that, the most plausible way for shareholders to realise value is corporate activity rather than organic recovery. The low valuation and fragmented share register make that possible, but nothing has been disclosed. Investors should size any position for binary outcomes and watch the AGM trading update, the Circana share data and the Chemist Warehouse renewal closely.
End of dossier. All figures are in AUD and from company filings unless otherwise noted. Items marked "not disclosed" or left blank in chartable tables were not found in the primary sources reviewed and have not been estimated. Derived figures (market capitalisation, shares on issue after the buyback, ratios, valuation multiples) are calculations from the cited filings and are labelled as such.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Appointed | Prior roles | Education |
|---|---|---|---|---|
Brett Charlton | CEO & Managing Director | 1 Aug 2023 | More than 30 years in consumer goods across Asia Pacific with Diageo, PepsiCo, Fonterra, Sanofi and private equity; later advisory and consulting | BCom (Marketing and HR), Griffith University; IMD Lausanne graduate; FAICD |
Mark Sherwin | Chief Financial Officer | 6 May 2024 | Not detailed in the sources reviewed | — |
Craig Durham | General Counsel & Company Secretary (not KMP) | 15 Jan 2024 | 35-year career in legal and governance roles in beverages, intelligent traffic systems, gaming technology and financial services | LLB (Hons) QUT; LLM Melbourne; Grad Dip Legal Practice; Grad Dip Applied Corporate Governance; FGIA; GAICD; admitted in Qld, Vic and New York |
“—” = not publicly disclosed.
Directors' Remuneration
| Component | B. Charlton FY2025 | B. Charlton FY2026 | M. Sherwin FY2025 | M. Sherwin FY2026 |
|---|---|---|---|---|
Salary and fees | 618,900 | 631,146 | 448,068 | 458,755 |
Annual leave accrual | 9,449 | 19,043 | 7,656 | 10,152 |
Cash bonus (one-off discretionary) | 0 | 93,780 | 0 | 44,800 |
Superannuation | 30,000 | 30,000 | 29,932 | 30,000 |
Long service leave | 3,035 | 8,499 | 1,838 | 4,968 |
Share-based payments | -139,897 | 70,825 | 2,495 | 14,388 |
Total remuneration | 521,487 | 853,293 | 489,989 | 563,063 |
Board of Directors
| Director | Role | Independent | Appointed | Committees | Background | Shares held |
|---|---|---|---|---|---|---|
Ari Mervis | Chair (21 Jul 2021–10 Mar 2025; again from 1 Feb 2026) | Yes | 16 Feb 2021 | Chair, Nominations | Former Chair and Executive Chair of Endeavour Group; Executive Chair of Accolade Wines; CEO & MD of Murray Goulburn; SABMiller (CEO CUB, MD Asia Pacific). BCom, University of the Witwatersrand. Former Myer director (2021–2024). | 150,000 |
Brett Charlton | CEO & MD | No | 1 Aug 2023 | — | See above | 100,000 |
Alison Cook | NED; interim Chair 10 Mar 2025–31 Jan 2026 | Yes | 24 Jul 2018 | Chair, Remuneration, People & Culture; member, Audit & Risk and Nominations | Former COO and CEO of Genetic Technologies (ASX/NASDAQ); 30+ years in biopharma. BSc, MSc (Microbiology); GAICD | 35,500 |
Helen Thornton | NED | Yes | 20 Dec 2021 | Chair, Audit & Risk; member, Remuneration, People & Culture and Nominations | Chartered Accountant; former VP Risk Management at BlueScope; BHP, Deloitte, KPMG. NED of Arena REIT, Ansvar Insurance and Beyond Bank. BEc, Monash | 20,000 |
John Batistich | NED | Yes | 17 Nov 2025 | Member, Audit & Risk, Remuneration, People & Culture, and Nominations | Marketing and digital executive at Westfield, PepsiCo, Kimberly-Clark, Wrigley and Lion Nathan. NED of Adairs and Foodco; former NED of Zip Co (2018–2024). BBus, MMgt; GAICD | 80,000 |
Jane McKellar | NED (retired 31 Jan 2026) | Yes | Not stated in sources | Former Chair, People & Culture | — | 11533 (at retirement) |
Board & Management Changes
| Date | Change |
|---|---|
10 Dec 2020 | Laurence McAllister departs as CEO & MD; Grant Peck becomes interim CEO |
31 Mar 2021 | Peck becomes permanent CEO & MD |
21 Jul 2021 | Mervis succeeds Graham Cubbin as Chair |
| 2023 | Peck departs; he later became non-executive chair of Mighty Craft. Exact exit date not in sources reviewed. |
1 Aug 2023 | Brett Charlton becomes CEO & MD |
15 Jan 2024 | Craig Durham becomes General Counsel & Company Secretary |
30 Apr 2024 | CFO Paul Witheridge retires |
6 May 2024 | Mark Sherwin becomes CFO |
10 Mar 2025 | Mervis steps down as Chair; Cook becomes interim Chair |
17 Nov 2025 | Batistich joins the board |
31 Jan / 1 Feb 2026 | McKellar retires; Mervis resumes as Chair; committees restructured |
Major Shareholders
| Holder | Shares | % | Source / date |
|---|---|---|---|
Investors Mutual Limited | 12,495,860 | 8.68 | InvestSMART substantial-holder register (date of notice not shown) |
Pinnacle Investment Management Group | 10,726,014 | 7.45 | InvestSMART substantial-holder register (date of notice not shown) |
Chemist Warehouse Group (now within Sigma Healthcare after their 2025 merger) | about 14.2M issued 1 Jul 2022 | 9.9 at issue | MCP release, 1 Jul 2022. Current holding not confirmed in the sources reviewed. |
Directors (combined, current board) | 385,500 | about 0.3 | FY26 Remuneration Report |
Competitive Landscape
Competitors by Segment
| Category (MCP brand) | Competitor | Owner / type | Notes |
|---|---|---|---|
Beauty tools (Manicare) | Retailer house brands (Chemist Warehouse, Priceline, Coles, Woolworths) | Private label | Main threat in a commoditised category |
Beauty tools (Manicare) | Tweezerman | Zwilling group | Premium tools |
Beauty tools (Manicare) | Revlon beauty tools | Revlon | Mass tools |
Cotton (Swisspers) | Supermarket and pharmacy private-label cotton | Private label | Swisspers holds 67.1% of the measured category |
Hair accessories (Lady Jayne) | Goody | Newell Brands | Global hair accessories |
Hair accessories (Lady Jayne) | Kitsch; scünci | Independent / Conair | Trend-led accessories |
Hair accessories (Lady Jayne) | Retailer house brands | Private label | — |
Facial skincare (Dr. LeWinn's) | L'Oréal (L'Oréal Paris, Garnier, CeraVe, La Roche-Posay) | L'Oréal | Dominant in pharmacy skincare |
Facial skincare (Dr. LeWinn's) | Olay | Procter & Gamble | Anti-ageing |
Facial skincare (Dr. LeWinn's) | Neutrogena | — | Mass derm |
Facial skincare (Dr. LeWinn's) | Nivea | Beiersdorf | Mass skincare |
Facial skincare (Dr. LeWinn's) | The Ordinary | Estée Lauder (DECIEM) | Value "science-led" positioning, a direct overlap |
Facial skincare (Dr. LeWinn's) | Natio; Sukin | Australian brands | Local challengers |
VMS (Fusion Health) | Blackmores | Kirin Holdings (acquired 2023) | Seller of Fusion; three-year non-compete expired in 2023 |
VMS (Fusion Health) | Swisse | H&H Group | Market leader |
VMS (Fusion Health) | Nature's Way; Herbs of Gold; Ethical Nutrients; Cenovis | Various | Herbal and practitioner overlap |
VMS (Fusion Health) | Wagner and other Chemist Warehouse house brands | Chemist Warehouse | MCP distributes some of these outside CWG, a co-opetition relationship |
Peer Comparison FY2026
| Company | Fiscal year | Revenue | Revenue growth | Margin indicator | R&D intensity |
|---|---|---|---|---|---|
McPherson's | FY26 (Jun) | AUD 118.3M | -14.9% | Underlying EBITDA margin 3.6%; gross margin 58.8% | — |
Beiersdorf | CY2024 | About EUR 9.9B | — | Not compiled in this research | Not compiled |
Haleon | CY2024 | About GBP 11.2B | — | Not compiled in this research | Not compiled |
Kenvue | CY2024 | About USD 15.5B | — | Not compiled in this research | Not compiled |
“—” = not publicly disclosed.
Recent Developments
--



